Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS
BMY Positive Sentiment
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Key Takeaway: The U.S. FDA has granted accelerated approval for Bristol Myers Squibb's ZENBEXUS, the company's first CELMoD therapy. This therapy is approved for use in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) in patients with multiple myeloma, particularly as early as the first relapse. This marks a significant advancement in treatment options for this patient population.
Market Sentiment Analysis
POSITIVE FACTORS
- FDA grants accelerated approval for ZENBEXUS therapy.
- Combination therapy shows promise for multiple myeloma patients.
- First CELMoD therapy from Bristol Myers Squibb.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
1.9%
average across 15 past catalysts
Lead asset
Muraglitazar
Phase 3 · Type 2 Diabetes
Frequently Asked Questions
What is ZENBEXUS?
ZENBEXUS is Bristol Myers Squibb's first CELMoD therapy approved for multiple myeloma.
What combination is ZENBEXUS used with?
ZENBEXUS is used in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone.
Who is the target patient group for ZENBEXUS?
ZENBEXUS is targeted at multiple myeloma patients, especially those experiencing early relapse.
What type of FDA approval did ZENBEXUS receive?
ZENBEXUS received accelerated approval from the U.S. FDA.